web analytics
-0.8 C
Saturday, November 26, 2022


AMARANTUS BIOSCI INC (OTCMKTS:AMBS) is trending up on accelerating volume after the Company recently reported positive top-line results of its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer’s disease (AD).

In recent news the Company said that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.

Gerald E. Commissiong, President & CEO of Amarantus, will provide a corporate update and a review of the Amarantus Diagnostics business and development strategy for the company’s therapeutic programs with a focus on investigational drug, eltoprazine, for the treatment of Parkinson’s disease levodopa-induced dyskinesias (PD-LID), on Tuesday, February 10, 2015, at 8:30 a.m. Eastern Standard Time.

AMBS has a history of highly explosive moves topping out at $0.20 twice in recent years; the first came after the historic November 6, 2012 release that Amgen Co-Founder Joseph Rubinfeld, PhD had joined AMBS Corporate Advisory Board.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”

The 2nd run up to $0.20 came earlier this year after news broke that AMBS Alzheimer’s disease (AD) blood test would be presented at two medical conferences in July 2014. The excitement surrounding the potential for the data sent AMBS stock skyward only to fall back down to earth right after the second presentation on July 31st in New York had concluded.

AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is developing LymPro, a blood test for the diagnosis of Alzheimer’s disease. Clearly there is a significant market demand for a product like LymPro that can quickly distinguish between patients with Alzheimer’s and other degenerative dementias such as Parkinson’s disease. dementia or old age-related memory loss.

Currently testing for Alzheimer’s is a lengthy, expensive and complicated process and with an overwhelming number of researchers and publications pointing to early diagnosis as critical to extending a patient’s quality of life the demand for a product such as LymPro grows.

Amarantus Bioscience Holdings is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine, a Phase 2b-ready small molecule drug indicated for Parkinson’s Levodopa induced dyskinesia and adult ADHD.

AMBS also has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). Amarantus is developing MANF-based products as treatments for orphan ophthalmological disorders and other indications.

As well AMBS owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard). Amarantus operations are located in offices and labs at Janssen Labs.

MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. Our lead MANF product development effort is centered on a therapy for Parkinson’s disease.

We Have a MASSIVE Stock Pick Coming ASAP. Only a Crazy Person would Miss this!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Back in 2012 the Company entered into an exclusive worldwide license agreement with the University of Massachusetts Medical School for intellectual property surrounding the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) as both a biomarker and a treatment for beta cell-degenerating disorders (the “License”).

The license agreement includes all intellectual property covering the use of MANF as a biomarker and treatment for beta cell degeneration disorders, including Wolfram syndrome, Type-1 diabetes and Type-2 diabetes. The License expands the company’s extensive intellectual property portfolio for MANF, including composition of matter and method of use patents and patent applications worldwide for MANF and derivative sequences for protein therapy, gene therapy and cell therapy applications.

On October 9 AMBS announced positive data from its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer’s disease (AD). LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls. As a result of these positive findings, Amarantus is expanding the study to assess LymPro’s predictive value in diagnosing early-stage AD patients. Amarantus anticipates launching LymPro in the fourth quarter of 2014.

AMBS continues to be one of the top traded stocks on the entire OTC market offering plenty of volatility for traders. The stock has a history of spectacular moves running form sub pennies to $0.20 a share back in early 2013 for 1000% + gains. The stock is currently trading near proven support levels of $0.067 and $0.05 and continues to hold strong on positive investor sentiment and steady accumulation.

For more info on AMBS Please Subscribe below, also you should know we have Something Huge Coming!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AMBS either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.